ZW10192A1 - Conjugates - Google Patents

Conjugates

Info

Publication number
ZW10192A1
ZW10192A1 ZW101/92A ZW10192A ZW10192A1 ZW 10192 A1 ZW10192 A1 ZW 10192A1 ZW 101/92 A ZW101/92 A ZW 101/92A ZW 10192 A ZW10192 A ZW 10192A ZW 10192 A1 ZW10192 A1 ZW 10192A1
Authority
ZW
Zimbabwe
Prior art keywords
antibody
conjugates
toxin
tumours
treating gastrointestinal
Prior art date
Application number
ZW101/92A
Other languages
English (en)
Inventor
Firman Wright Andrew
Charles Blakey David
Edward Fitton John
Lindholm Leif
Lind Peter
Homgren Jan
Original Assignee
Ici Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ici Plc filed Critical Ici Plc
Publication of ZW10192A1 publication Critical patent/ZW10192A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44Antibodies bound to carriers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046Stomach, Intestines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Semiconductor Lasers (AREA)
  • Bipolar Transistors (AREA)
  • Metal-Oxide And Bipolar Metal-Oxide Semiconductor Integrated Circuits (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZW101/92A 1991-07-03 1992-07-03 Conjugates ZW10192A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB919114399A GB9114399D0 (en) 1991-07-03 1991-07-03 Conjugates

Publications (1)

Publication Number Publication Date
ZW10192A1 true ZW10192A1 (en) 1993-03-31

Family

ID=10697775

Family Applications (1)

Application Number Title Priority Date Filing Date
ZW101/92A ZW10192A1 (en) 1991-07-03 1992-07-03 Conjugates

Country Status (24)

Country Link
EP (1) EP0528527B1 (es)
JP (1) JP3735379B2 (es)
KR (1) KR100252147B1 (es)
AT (1) ATE164768T1 (es)
AU (1) AU665546B2 (es)
CA (1) CA2073113C (es)
CZ (1) CZ209792A3 (es)
DE (1) DE69225035T2 (es)
DK (1) DK0528527T3 (es)
ES (1) ES2113923T3 (es)
FI (1) FI106928B (es)
GB (2) GB9114399D0 (es)
GR (1) GR3026575T3 (es)
HU (1) HU215243B (es)
IE (1) IE922190A1 (es)
IL (1) IL102399A (es)
MY (1) MY110513A (es)
NO (1) NO308539B1 (es)
NZ (1) NZ243437A (es)
PT (1) PT100660B (es)
SK (1) SK209792A3 (es)
TW (1) TW329425B (es)
ZA (1) ZA924973B (es)
ZW (1) ZW10192A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5686121A (en) * 1979-12-14 1981-07-13 Teijin Ltd Antitumor proten complex and its preparation
EP0170697B1 (en) 1984-02-08 1991-10-23 Cetus Oncology Corporation Toxin conjugates
US5165923A (en) * 1989-11-20 1992-11-24 Imperial Cancer Research Technology Methods and compositions for the treatment of hodgkin's disease
HU218603B (hu) * 1990-07-20 2000-10-28 Kabi Pharmacia Ab Célspecifikus antitest-szuperantigén konjugátumok és ezen készítmények előállítása

Also Published As

Publication number Publication date
IL102399A (en) 2003-05-29
PT100660A (pt) 1993-10-29
DK0528527T3 (da) 1999-01-18
IL102399A0 (en) 1993-01-14
KR100252147B1 (ko) 2000-09-01
TW329425B (en) 1998-04-11
CZ209792A3 (en) 1993-01-13
CA2073113C (en) 2004-09-14
ES2113923T3 (es) 1998-05-16
CA2073113A1 (en) 1993-01-04
DE69225035D1 (de) 1998-05-14
AU1943092A (en) 1993-01-07
HU9202219D0 (en) 1992-10-28
NZ243437A (en) 1994-10-26
FI923085A0 (fi) 1992-07-03
DE69225035T2 (de) 1998-08-13
EP0528527A3 (en) 1993-03-17
GR3026575T3 (en) 1998-07-31
HUT67048A (en) 1995-01-30
FI106928B (fi) 2001-05-15
NO922383D0 (no) 1992-06-17
KR930001928A (ko) 1993-02-22
IE922190A1 (en) 1993-01-13
EP0528527B1 (en) 1998-04-08
ATE164768T1 (de) 1998-04-15
FI923085A (fi) 1993-01-04
JPH05320065A (ja) 1993-12-03
SK209792A3 (en) 1994-06-08
GB9114399D0 (en) 1991-08-21
AU665546B2 (en) 1996-01-11
HU215243B (hu) 1998-11-30
NO922383L (no) 1993-01-04
EP0528527A2 (en) 1993-02-24
ZA924973B (en) 1993-04-28
MY110513A (en) 1998-07-31
PT100660B (pt) 1999-06-30
NO308539B1 (no) 2000-09-25
GB9212880D0 (en) 1992-07-29
JP3735379B2 (ja) 2006-01-18

Similar Documents

Publication Publication Date Title
HUT70200A (en) Process for producing macrocyclic bifunctional chelants, complexes thereof, their antibody conjugates and pharmaceutical compositions containing them
AU2948084A (en) Cytotoxic toxin-antibody conjugate compositions
ATE144523T1 (de) Glykosylierte arzneimittel-vorstufen, verfahren zu ihrer herstellung und ihre verwendungen
IL68106A0 (en) Immunoenzymic conjugates,their preparation and medicinal associations of such conjugates with immunotoxins
IL97776A0 (en) Antibody conjugates for treatment of neoplastic diseases
HU9203649D0 (en) Method for producing inclusion compounds of nimesulide with cyclodextrines and pharmaceutical preparatives containing these compounds
IL102399A0 (en) Conjugates
ATE1853T1 (de) 5,12-dihydroxy-1,2,3,4,6,11-hexahydro-2,6,11trioxonaphthacene und deren synthese.
NO943847L (no) Fremgangsmåte for fremstilling av makrocykliske chelateringsmidler og dannelse av chelater og konjugater derav